AAV Durability: The road to a one-shot cure

Inconsistent long-term clinical data has highlighted the need to better understand the durability of AAV-based gene therapies.

We assessed 121 different clinical trials across the 4 main target tissue types – liver, muscle, CNS and ocular tissues. As well as extracting and summarising specific durability data, we explored key findings across tissues, trials, routes of administration, doses and serotypes.

Through the comprehensive report that we have produced, we intend to provide gene therapy developers with valuable insights on the durability of the current generation of therapies across the disease landscape.

To download your copy of the full report, please submit the details using the form on the right.  A copy of the report will automatically download after submission.

Do you have a future market research project that you’d like to discuss with us?

  • AAV-based gene therapies